Live Breaking News & Updates on Nasdaq Cdtx

Stay updated with breaking news from Nasdaq cdtx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Rating of "Buy" by Analysts

Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) have received an average rating of “Buy” from the four brokerages that are presently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year […] ....

United States , Needham Company , Flagship Harbor Advisors , Cantor Fitzgerald , Cidara Therapeutics Company Profile , Raymond James Financial Services Advisors Inc , Cidara Therapeutics Inc , Cidara Therapeutics , Get Free Report , Marketbeat Ratings , James Financial Services Advisors , Harbor Advisors , Pale Fire Capital , Get Free , Cidara Therapeutics Daily , Nasdaq Cdtx ,

Cidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst Upgrade

Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) gapped up prior to trading on Thursday after Needham & Company LLC raised their price target on the stock from $3.00 to $25.00. The stock had previously closed at $12.29, but opened at $14.50. Needham & Company LLC currently has a buy rating on the […] ....

United States , Raymond James Financial Services Advisors Inc , Needham Company , Cidara Therapeutics Company Profile , Flagship Harbor Advisors , Cantor Fitzgerald , Cidara Therapeutics Inc , Cidara Therapeutics , Get Free Report , Harbor Advisors , James Financial Services Advisors , Pale Fire Capital , Cidara Therapeutics Daily , Nasdaq Cdtx ,

WBB Securities Reaffirms "Strong-Buy" Rating for Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics (NASDAQ:CDTX – Get Free Report)‘s stock had its “strong-buy” rating reiterated by stock analysts at WBB Securities in a note issued to investors on Thursday, Benzinga reports. They currently have a $40.00 price target on the biotechnology company’s stock. WBB Securities’ price target would indicate a potential upside of 207.69% from the stock’s […] ....

United States , Cidara Therapeutics Inc , Needham Company , Raymond James Financial Services Advisors Inc , Flagship Harbor Advisors , Cantor Fitzgerald , Cidara Therapeutics , Get Free Report , James Financial Services Advisors , Fire Capital , Cidara Therapeutics Daily , Nasdaq Cdtx , Reiterated Rating , Wbb Securities ,

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Given Consensus Rating of "Buy" by Brokerages

Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) have received a consensus recommendation of “Buy” from the four analysts that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target […] ....

United States , Flagship Harbor Advisors , Cidara Therapeutics Inc , Needham Company , Raymond James Financial Services Advisors Inc , Cantor Fitzgerald , Cidara Therapeutics , Get Free Report , James Financial Services Advisors , Harbor Advisors , Pale Fire Capital , Get Free , Cidara Therapeutics Daily , Nasdaq Cdtx ,

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of "Buy" by Brokerages

Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) have received an average recommendation of “Buy” from the four brokerages that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 […] ....

United States , Needham Company , Cidara Therapeutics Inc , Cantor Fitzgerald , Raymond James Financial Services Advisors Inc , Flagship Harbor Advisors , Cidara Therapeutics , Get Free Report , Marketbeat Ratings , James Financial Services Advisors , Harbor Advisors , Pale Fire Capital , Get Free , Cidara Therapeutics Daily , Nasdaq Cdtx ,